周三，BMO Capital Markets维持对Legend Biotech Corp（NASDAQ:LEGN）股票的"优于大市"评级，目标价保持在90.00美元不变。该公司分析师强调，年初至今投资者情绪呈现积极趋势，Legend ...

传奇生物公布2024年第四季度和全年业绩及近期亮点： 1. CARVYKTI2024年第四季度和全年的净贸易销售额分别约为3.34亿美元和9.63亿美元 2. 截至目前，已有逾5000例患者接受了治疗 3. CARVYKTI已在诺华生产基地启动商业化生产 4. 西班牙国家卫生系统已批准CARVYKTI纳入多发性骨髓瘤患者的二线及以上治疗的报销范围 5. 截至2024年12月31日，现金及现金等价物 ...

周三，H.C. Wainwright调整了对Legend Biotech Corp. (NASDAQ: LEGN )的展望，将12个月目标价从73.00美元上调至75.00美元，并维持对该公司股票的"买入"评级。根据InvestingPro数据显示，该股票目前交易价格低于其公允价值，分析师目标价区间为53美元至95美元。此次调整是基于Legend ...

DelveInsight's "CARVYKTI Market Size, Forecast, and Market Insight Report" highlights the details around CARVYKTI, a ...

Despite initial caution, Carvykti's sales surged, reaching $334M in Q4 2024, driving Legend Biotech Corporation to net income and solidifying its market position. Legend's financial health is ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

Johnson & Johnson and Legend Biotech’s BCMA-targeted CAR-T therapy Carvykti has been approved by the FDA to treat patients with multiple myeloma after at least one prior therapy. The decision ...

We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as “ANI per Share”) as performance metrics. Adjusted Net Loss and ANI per Share are not defined under IFRS ...

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production ...

Following the prepared remarks, we will open up the call for Q&A. We have our President of CARVYKTI, Alan Bash; President of R&D, Guowei Fang; and Chief Medical Officer, Mythili Koneru ...